Atripla - 54868-5643-0 - (efavirenz, emtricitabine, and tenofovir disoproxil fumarate)

Alphabetical Index


Drug Information of Atripla

Product NDC: 54868-5643
Proprietary Name: Atripla
Non Proprietary Name: efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Active Ingredient(s): 600; 200; 300    mg/1; mg/1; mg/1 & nbsp;   efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Administration Route(s): ORAL
Dosage Form(s): TABLET, FILM COATED
Coding System: National Drug Codes(NDC)

Labeler Information of Atripla

Product NDC: 54868-5643
Labeler Name: Physicians Total Care, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA021937
Marketing Category: NDA
Start Marketing Date: 20121016

Package Information of Atripla

Package NDC: 54868-5643-0
Package Description: 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (54868-5643-0)

NDC Information of Atripla

NDC Code 54868-5643-0
Proprietary Name Atripla
Package Description 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (54868-5643-0)
Product NDC 54868-5643
Product Type Name HUMAN PRESCRIPTION DRUG
Non Proprietary Name efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Dosage Form Name TABLET, FILM COATED
Route Name ORAL
Start Marketing Date 20121016
Marketing Category Name NDA
Labeler Name Physicians Total Care, Inc.
Substance Name EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Strength Number 600; 200; 300
Strength Unit mg/1; mg/1; mg/1
Pharmaceutical Classes Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]

Complete Information of Atripla


General Information